- Molecular NameValrubicin
- SynonymAntibiotic Ad 32
- Weight723.65
- Drugbank_IDDB00385
- ACS_NO56124-62-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.43
- pkaN/A
- LogD (pH=7, predicted)3.43
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-6.95
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors5
- No.of HBond Acceptors14
- No.of Rotatable Bonds12
- TPSA215.22
- StatusFDA approved
- AdministrationIntravesical
- PharmacologyA chemotherapy drug used to treat bladder cancer.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein binding99.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmValrubicin is metabolized to two primary metabolites: N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol.
- Half lifeN/A
- ExcretionIn urine
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m2.
- LD50 (rat)N/A
- LD50 (mouse)N/A